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Selective reduction of astrocyte apoE3
and apoE4 strongly reduces Aβ accumulation
and plaque-related pathology in a mouse
model of amyloidosis
Thomas E. Mahan†, Chao Wang†, Xin Bao, Ankit Choudhury, Jason D. Ulrich and David M. Holtzman*

Abstract
Background: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β
(Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset
AD and has been shown to influence the accumulation of Aβ in the brain in an isoform-dependent manner. ApoE can
be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive
microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of Aβ plaque pathology, it is not fully known how apoE produced by specific cell types, such
as astrocytes, contributes to amyloid pathology.
Methods: We utilized APOE knock-in mice capable of having APOE selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP/PS1-21 mouse model of amyloidosis. We analyzed the changes
to Aβ plaque levels and assessed the impact on cellular responses to Aβ plaques when astrocytic APOE is removed.
Results: Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing
astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large
decrease in Aβ plaque deposition and less compact plaques. While overall Iba1+ microglia were unchanged in the
cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE
were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are
unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a
reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around remaining individual plaques was
increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy
was significantly decreased.
Conclusion: This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation
of Aβ plaques as well as on certain Aβ-associated downstream effects.
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Background
Alzheimer disease (AD) is the leading cause of dementia, affecting over 6 million Americans and ~ 50 million
people worldwide [1, 2]. The strongest genetic risk factor
for developing late-onset AD is apolipoprotein E (APOE)
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genotype. The influence of APOE on AD risk occurs in an
isoform-dependent manner (ε2 < ε3 < ε4) [3–6]. One way
apoE affects AD risk is through facilitating the formation of amyloid plaques, the earliest detectable pathological hallmark of AD [7–9]. ApoE is found as a constituent
in amyloid plaques, suggesting it can directly facilitate
plaque formation, and apoE affects amyloid deposition in
an isoform and expression-level dependent manner [10–
17]. APOE4 carriers exhibit more amyloid pathology than
non-carriers and mouse models of β-amyloidosis with
the human APOE4 gene knocked in develop more amyloid than those with APOE3 [12, 15, 18–23]. The effect
of apoE on Aβ is also dependent on the amount of apoE
in the brain. Knockout of Apoe strongly reduces amyloid
deposition in mouse models of amyloid deposition [13,
14, 24]. Mice that are hemizygous for APOE develop less
Aβ plaque than mice homozygous for APOE [14, 15, 21,
25]. Additionally, reduction of apoE levels prior to plaque
onset using apoE-targeted anti-sense oligonucleotides
(ASO’s), results in reduced Aβ plaque pathology [26].
Conversely, overexpression of ApoE4 during the nascent
stages of plaque formation leads to an increase in amyloid plaque deposition [27].
Within the brain, APOE is predominantly expressed
by astrocytes under physiological conditions. However,
when damage occurs in the brain, microglia significantly
upregulate APOE expression [28–30]. In mouse models of amyloid pathology, plaque-associated microglia
exhibit high levels of apoE expression as part of a broader
“microglial neurodegenerative phenotype” (MGnD) or
“disease-associated microglia” (DAM) transcriptional
profile [28, 29, 31]. Microglial apoE expression may be
critical for the microglial responses to injury in the brain
since microglial activation is attenuated by germ line
Apoe KO in mouse models of amyloid or tau pathology
[24, 32]. Previous research from our lab has shown that
microglia expressing human APOE2, APOE3, or APOE4
produce apoE-containing lipoprotein particles that are
smaller in size than particles produced by astrocytes [33].
The difference in apoE particle size in astrocytes and
microglia raises the question as to whether or not apoEcontaining lipoprotein particles produced by each cell
type may have differential effects on the development of
Aβ pathology.
Microglia-derived apoE can deposit within amyloid
plaques and may contribute to plaque formation and
influence morphology [34]. Other studies found selective
removal of murine apoE from astrocytes in APPPS1ΔE9
mice reduces Aβ plaque burden [35]. Conversely, overexpression of APOE4, but not APOE3, in astrocytes
exacerbated Aβ pathology, suggesting that astrocytederived human apoE may differentially affect amyloid
pathology [27]. Whether astrocyte-specific expression
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of endogenously produced human APOE isoforms influences Aβ pathology, glial reactivity to Aβ plaque deposition, or downstream effects of Aβ deposition has not
been investigated. To assess how the loss of astrocytic
APOE impacts Aβ pathology, we used Aldh1l1-Cre/ERT2
BAC transgenic mice, in which the Aldh1l1 promoter
drives expression of a tamoxifen-inducible Cre recombinase specifically in astrocytes, crossed with APPPS1-21/
APOE3 or APOE4 knock-in mice.

Methods
Contact for reagent and resource sharing

Further information and requests for resources and reagents should be directed to David M. Holtzman (holtz
man@wustl.edu).
Experimental model and subject details

APPPS1–21 mice on a C57BL/6 N background (gift from
Dr. Mathias Jucker, Department of Cellular Neurology,
Hertie Institute for Clinical Brain Research, University
of Tübingen, Germany) overexpress human APP bearing both the Swedish mutation and PSEN1 containing
an L166P mutation, both driven by the Thy1 promoter
[36]. ApoE3flox/flox and apoE4flox/flox (FE3 and FE4, respectively), human APOE knock-in mice on a C57BL background, were generated by replacing the mouse genomic
sequence from the translation initiation codon in exon
2 to the termination codon in exon 4 with its human
counterparts flanked by loxP site, driven by the endogenous APOE promoter [33]. Aldh1l1-Cre/ERT2 mice on
a C57BL background were obtained from Jackson Laboratories (Stock No. 031008). To generate APPPS1-21/
apoE3flox/flox or 
apoE4flox/flox mice (APPPS1;FE3Cre- or
APPPS1;FE4Cre-, respectively, and collectively referred
to as Cre-), we crossed APPPS1-21 transgenic mice with
FE3 or FE4 for several generations. To generate Aldh1l1Cre/ERT2/apoE3flox/flox or 
apoE4flox/flox mice (AFE3 or
AFE4, respectively), we crossed Aldh1l1-Cre/ERT2
mice to FE3 or FE4 for several generations. We then
crossed APPPS1;FE3Cre- or APPPS1;FE4Cre- mice to
AFE3 or AFE4 mice, respectively, to produce APPPS121/Aldh1l1-Cre/apoE3flox/flox or a
poE4flox/flox mice
(APPPS1;FE3Cre + or APPPS1;FE4Cre+, respectively,
and collectively referred to as Cre+). Finally, we crossed
APPPS1;FE3Cre + or APPPS1;FE4Cre + mice to FE3 or
FE4 mice, respectively, to produce experimental mice
utilized. All the experimental mice involved in the final
analysis were obtained from the same generation. The
sex of animals in each specific experiment can be found
in the corresponding figure legends. All animal procedures and experiments were performed under guidelines approved by the Institutional Animal Care and Use
Committee (IACUC) at Washington University School of
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Medicine. All of the phenotyping and data analysis was
performed by researchers who were blind to the genotype of the mice.

Methods details
Tamoxifen administration

Tamoxifen was dissolved in corn oil at a concentration
of 20 mg/ml by shaking overnight at 37 °C. After preparation, the tamoxifen solution was wrapped by foil, and
stored at 4 °C for up to a month. Tamoxifen was given at
100 mg tamoxifen/kg body weight and administered via
intraperitoneal (IP) injection once every 24 h for 6 consecutive days. All experimental mice received the same
series of IP tamoxifen injections over 6 days.
Brain isolation and preparation

Mice were anesthetized with 200 mg/kg pentobarbital and subsequently perfused with cold PBS containing 3 IU/ml heparin. After brain isolation, the left
hemisphere was fixed in 4% paraformaldehyde for at least
24 h and then transferred to 30% sucrose and stored at
4 °C until sectioning. The right hemisphere was dissected
into various parts (posterior- and anterior-cortex, hippocampus, etc.), all of which were snap-frozen using dry
ice and stored at − 80 °C until further analysis.
Histology and image acquisition

Hippocampal-containing sections were selected for
human apoE (Cell Signaling, 13,366, 1:500), GFAP
(Abcam, ab53554, 1:500; Millipore, MAB3402B, 1:2000),
Iba1 (Abcam, ab5076, 1:500; Wako, 019–19,741, 1:5000),
Aβ (HJ3.4, in house, mouse monoclonal, 2 μg/ml),
Clec7a (InviviGen, mabg-mdect, 1:50), BACE1 (Abcam,
ab108394, 1:100), and RTN-3 (a generous gift from Dr.
Riqiang Yang, 1:1000) immunofluorescence staining. For
reticulon-3 (RTN-3) staining, sections were pre-mounted
on to Superfrost + glass microscope slides. For all other
stainings, sections were free-floating. Sections were
washed in Tris-buffered saline (TBS) buffer for 3 times,
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5 min each. After washing, sections were incubated in
TBS with 0.25% Triton X-100 (TBSX) for 30 min at room
temperature to permeabilize the sections, followed by 1
time TBS washing for 5 min. Then sections were incubated with 2 μM X34 in the X-34 staining buffer (40%
ethanol, 60% TBS, 1:500 vol. 10 N NaOH) for 20 min.
After X-34 staining, sections were washed 3 times for
2 min each in the X-34 washing buffer (40% ethanol and
60% TBS), followed by 3 times washing in TBS for 5 min
each. For RTN-3 staining, antigen retrieval was performed by heating sections to 95 °C in 50 nM Sodium
Citrate buffer for 30 min followed by 3 times washing in
TBS for 5 min each. After washing, sections were blocked
by 10% donkey serum in TBSX for 1 h at room temperature to prevent non-specific binding. Then sections were
incubated with primary antibodies at 4 °C, overnight.
After overnight incubation, sections were washed 3 times
in TBS for 5 min each. Then sections were incubated with
corresponding secondary fluorescence antibodies (Life
Technologies) for 2 h at room temperature. After 3 times
washing by TBS for 10 min each, sections were mounted
to glass slides. Slides were coverslipped by ProLong Glass
Antifade Mountant (Invitrogen, P36980) and scanned by
Nikon A1Rsi Confocal Microscope, Leica Stellaris 5, or
BioTek Cytation5. Representative images in Fig. 1E were
captured by the BioTek Cytation5 using a 10X objective.
Representative images in Figs. 2A, 3A, 4A, 5C (top panel),
6A, S1, and S2A were captured by the BioTek Cytation5
using a 4X objective. Representative images in Figs. 3F,
6C, E, S2B, and S5 were captured by the BioTek Cytation5
using a 20X objective. Representative images in Figs. 1G,
2D, 4C, and E were captured by the Leica Stellaris 5 using
a 40X oil objective. Representative images in Fig. 5B (bottom panel) were captured by the Nikon A1Rsi using a
40X objective.
Image processing and quantification

Acquired images were analyzed by using Image J v1.53c
(https://imagej.net/Fiji), Imaris 9 (https://imaris.oxinst.

(See figure on next page.)
Fig. 1 Tamoxifen administration reduces ApoE levels in Aldh1l1-Cre + APPPS1;FE3Cre- and APPPS1;FE4Cre- mice. A Timeline of the experimental
scheme. Mice were given once-daily IP injections of tamoxifen (TAM) (100 mg TAM/kg body weight) at 4 weeks of age for 6 consecutive days.
Sample collection and analysis occurred at 18 weeks of age. B APOE mRNA expression levels in Cre- and Cre + FE3, FE4, APPPS1;FE3, and
APPPS1;FE4 mice. Cortical tissue samples were analyzed by qPCR (n = 9). C Soluble apoE levels in the cortex of Cre- or Cre + mice. Cortical tissue
samples were homogenized in PBS and PBS-soluble apoE protein levels were analyzed by ELISA (n = 9–19). D Insoluble apoE levels in the cortex
of Cre- or Cre + mice. PBS-insoluble cortex tissue samples from (C) were further homogenized in 5 M guanidine HCl to determine the amount
of PBS-insoluble apoE that was guanidine-soluble. Protein levels were analyzed by ELISA (n = 9–19). E ApoE immunostaining in the cortex and
hippocampus of Cre-and Cre + mice. Representative images are of female brain sections stained with an anti-apoE antibody. Scale bars = 300 μm.
F Intensity of fluorescent apoE staining in Cre- or Cre + mice. The average pixel intensity was analyzed from images of apoE immunostained brain
sections (n = 10–19). G Brain sections from female APPPS1;FE4Cre- and APPPS1;FE4Cre + mice co-stained for X-34 (blue), apoE (green), GFAP (red),
and Iba1 (magenta). White arrows indicate co-localization of apoE with GFAP and green arrows indicate co-localization of apoE with Iba1. Scale
bars = 50 μm. A-G * p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 0.0001; two-way ANOVA and Sidak’s post hoc test in (B), three-way ANOVA and Sidak’s post
hoc test in (D); three-way ANOVA and uncorrected Fisher’s LSD test in (C) and (F). Data are expressed as mean ± SEM. See Supplementary Table 1 for
detailed statistics
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com/), and BioTek Gen5 (https://www.biotek.com/produ
cts/software-robotics/) software. ApoE fluorescent staining intensity in Fig. 1F was determined using images captured by the BioTek Cytation5. The average pixel intensity
for each image was found by setting a minimal threshold
to highlight positive staining, running the “Analyze Particle” function to obtain the mean pixel intensity, and
then subtracting the average background pixel intensity.
The average background pixel intensity was determined
by calculating the average pixel intensity of APPPS1EKO
images. To determine the percent of hippocampal area
or cortical area covered by X-34, HJ3.4, Iba1, GFAP, or
BACE1 in Figs. 2B, C, 3B, C, 4B, 5D, and 6B, images were
analyzed as previously described [37, 38]. Briefly, Image
J software was used to analyze images captured with the
BioTek Cytation5. Regions of interest (ROI’s) of images
were traced, images were thresholded to highlight positive staining, and the “Analyze Particle” function was used
to obtain the percent area covered. While intense BACE1
staining was present in the hippocampus, quantification
of the hippocampus was excluded because high levels of
BACE1 in the mossy fibers are physiologically normal
and not indicative of any neuritic dystrophy. The average intensity of fibrillar plaques in Fig. 2E was also found
using ImageJ software to analyze images of X-34 stained
sections captured with the BioTek Cytation5 software.
The cortex was traced, images were thresholded to highlight positive staining, and the “Analyze Particle” function was used to obtain the average pixel intensity. The
X-34 to HJ3.4 ratio in 3G was determined using images
of the cortex captured with the BioTek Cytation5 and analyzed using ImageJ software. Images were thresholded
to highlight positive staining, and the “Analyze Particle”
function was used to obtain the percent area covered.
The area of X-34 was then divided by the area of HJ3.4.
To determine the percent area of Clec7a and Iba1 staining around X-34 plaques in Fig. 4E, ImageJ software was
used to analyze images captured with the Leica Stellaris 5
confocal microscope. The images of X-34+ plaques were
thresholded to highlight plaques, “Analyze Particles” was
run, and the thresholded plaque ROI’s were combined
and then enlarged by 15 μm. The enlarged ROI’s were then
transferred to the corresponding Clec7a and Iba1 images,
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images were thresholded, and “Analyze Particles” was run
to find the area of Clec7a and Iba1. The area of Clec7a
was then divided by the area of Iba1. The GFAP volume to
X-34 volume in Fig. 5D was found using Imaris software
to analyze images obtained by the Nikon A1Rsi confocal
microscope, as previously described [24]. Briefly, Surfaces
were created for X-34 and GFAP and the Dilate Xtension
was used to dilate the X-34 surfaces by 15 μm. The surface-surface co-localization Xtension was run using the
dilated X-34 surfaces and GFAP surfaces and the volume
of GFAP within 15 μm of X-34 plaque was determined
based on overall X-34 plaque volume. The BACE1 and
RTN-3 area per X-34 plaque was determined using BioTek
Gen5 software to analyze images obtained by the BioTek
Cytation5. The Cellular Analysis function was used with
the primary mask thresholded and set based on the X-34
staining. The secondary mask was set using a 15 μm
expanded distance from the X-34 primary mask, BACE1
and RTN-3 staining was thresholded, and the average
BACE1 area per X-34 plaque and RTN-3 area per X-34
plaque was determined. To determine the amount of apoE
area per Iba1 area around plaques, images were obtained
with the Leica Stellaris5 confocal microscope. The images
of X-34+ plaques were subtracted from the corresponding apoE images to remove any apoE signal co-localized
with X-34, leaving only non-plaque associated apoE. The
images of X-34+ plaques were then thresholded to highlight plaques, “Analyze Particles” was run, and the thresholded plaque ROI’s were combined and then enlarged
by 10 μm. The enlarged ROI’s were then transferred to the
corresponding apoE and Iba1 images, images were thresholded, and “Analyze Particles” was run to find the area
of apoE and Iba1 around the plaque. To determine what
apoE was located within microglia, the Iba1 images were
subtracted from the corresponding apoE images to leave
apoE not co-localized with Iba1. The remaining area of
apoE around plaques that was not co-localized with Iba1
was determined using the enlarged ROI, thresholding the
images, and running “Analyze Particles”. These areas were
then subtracted from the total apoE area around plaques
to determine the amount of apoE area that was co-localized with Iba1. The apoE area co-localized with Iba1 was
then divided by the total area of Iba1 around the plaques.

(See figure on next page.)
Fig. 2 Reducing astrocytic apoE decreases fibrillar plaque levels and plaque intensity. A Fibrillar amyloid plaque staining in the cortex and
hippocampus of female Cre-, Cre+, and APPPS1EKO mice. Representative images are of X-34 (blue) stained female brain sections. Scale
bars = 1000 μm (B) Fibrillar plaque load in the cortex of Cre-, Cre+, and APPPS1EKO mice. Percent of cortex area covered by fibrillar plaque was
determined by analyzing X-34 stained brain sections (n = 10–18). C Fibrillar plaque load in hippocampus of Cre-, Cre+, and APPPS1EKO mice.
Percent of hippocampus area covered by fibrillar plaque was determined by analyzing X-34 stained brain sections (n = 10–18). D Intensity of fibrillar
amyloid plaques in Cre-, Cre+, and APPPS1EKO mice. Representative images are of female X-34 stained amyloid plaques. Scale bars = 20 μm. E
Measure of average pixel intensity of X-34 stained fibrillar plaques in the cortex of Cre-, Cre+, and APPPS1EKO mice (n = 9–16). A-E * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001; three-way ANOVA and uncorrected Fisher’s LSD test in (B), (C), and (E). Data are expressed as
mean ± SEM. See Supplementary Table 1 for detailed statistics
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Brain tissue sample processing

Mouse posterior cortical tissue samples were sequentially
homogenized with cold PBS, and then 5 M guanidine
buffer in the presence of 1X Complete Protease Inhibitor
(Roche, 11,697,498,001) and 1X phosSTOP phosphatase
Inhibitor (Roche, 04906845001). First, tissues were
weighed, a half spoon of beads (Next Advance, ZrOB05)
were added, and samples were homogenized for 45 s
on setting 3, using a bead homogenizer (Next Advance,
Bullet Blender Strom 24), in cold PBS buffer at 20 μl
buffer/1 mg tissue. Homogenates were centrifuged 30 min
at 15,000 rpm at 4 °C. The supernatant was saved as the
PBS soluble fraction. Then the same amount of 5 M guanidine buffer was added to the pellet and homogenized on
bead homogenizer for 3 min on setting 8, followed by 1 h
rotation at room temperature. Finally, homogenates were
centrifuged for 30 min at 15,000 rpm at 4 °C. The supernatant was saved as the 5 M guanidine insoluble fraction.
All fractions were stored at − 80 °C until further analyzed.
Sandwich ELISA

The levels of apoE, Aβ40, and Aβ42 in PBS and 5 M guanidine fractions were measured by sandwich ELISA and
normalized to the tissue weight. The coating antibodies
for human apoE, Aβ40, and Aβ42 were HJ15.3 (in house,
mouse monoclonal, 5 μg/ml), HJ2 (in house, mouse
monoclonal, 20 μg/ml), and HJ7.4 (in house, mouse
monoclonal, 10 μg/ml), respectively [33, 39]. The capture
antibodies were HJ15.7-biotinylated (in house, mouse
monoclonal, 150 ng/ml) for human apoE and HJ5.1-biotinylated (in house, mouse monoclonal, 90 ng/ml) for both
Aβ40 and Aβ42 [33, 39].
Fluidigm biomark HD real‑time PCR

Both male and female mouse anterior cortex tissues
were used for the gene expression analysis. Nine samples from all APPPS1 positive groups were selected
based on the mean values of the X34 plaque load. Four
samples from APPPS1 negative FE3Cre-, FE4Cre-, and
FE4Cre + groups, 3 samples from APPPS1 negative
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FE3Cre + group were also used as the APPPS1 negative controls. mRNA was exacted from frozen tissues
using RNeasy Micro Kit (Qiagen, 74,004) and converted
to cDNA using the high-capacity RNA-to-cDNA kit
(Applied Biosystems, 4,387,406), following the manufacturer’s instructions. Gene expression was conducted
using Fluidigm Biomark HD Real-Time PCR System in
collaboration with Genome Technology Access Core
at Washington University. Using Taqman primers (Life
Technologies), the fold-changes were relative to FE3Creafter values were normalized to the mean values of
β-actin and Cyc1.
Western blotting

Mouse cortical tissues were lysed using RIPA buffer
(4°C). Samples were randomly selected and included 3
males and 3 females in each group. Complete Protease
Inhibitor and phosSTOP Phosphatase Inhibitor were
added freshly to the RIPA buffer. After weighing tissues, 50 μl cold RIPA/1 mg tissue and 1 spoon of beads
(ZrOB05) were added to the tissue-containing SafeLock microcentrifuge tubes. Tissues were homogenized
using a bead homogenizer (Bullet Blender Strom 24) on
setting 8 for 3 min. Homogenates were centrifuged in a
microcentrifuge at 15,000 rpm for 30 min at 4°C. Supernatant was collected for western blot. Micro BCA Protein
Assay Kit was utilized to measure protein concentration. Five micrograms of total protein was loaded and
separated by 4–12% NuPAGE gels in MOPS buffer. Gel
was transferred for 7 min on a nitrocellulose membrane
using the iBlot 2 system. After washing 3 times for 5 min
each with TBS buffer, including 0.05% Tween (TBST),
the membrane was blocked with 5% milk in TBST for 1 h
at room temperature, followed by incubation with APP
C-terminal antibody (Sigma, rabbit polyclonal, A8717,
1:1000) and α-tubulin antibody (mouse monoclonal,
66,031–1-lg, 1:15,000) at 4 °C. After overnight incubation, the membrane was incubated with corresponding
secondary HRP-conjugated secondary antibodies for 1 h
at room temperature. Images were captured using the

(See figure on next page.)
Fig. 3 Reducing astrocytic apoE decreases Aβ plaque levels and alters Aβ deposition. A Aβ plaque staining in the cortex and hippocampus of Cre-,
Cre+, and APPPS1EKO mice. Representative images are of Aβ immunostained female brain sections using the HJ3.4 anti-Aβ antibody (orange).
Scale bars = 1000 μm. B Aβ plaque load in cortex of Cre-, Cre+, and APPPS1EKO mice. Percent of cortex area covered by Aβ plaque was determined
by analyzing HJ3.4 stained brain sections (n = 10–18). C Aβ plaque load in the hippocampus of Cre-, Cre+, and APPPS1EKO mice. Percent of
hippocampus area covered by Aβ plaque was determined by analyzing HJ3.4 stained brain sections (n = 10–18). D Insoluble Aβ40 levels in the
cortex of Cre- and Cre + mice. PBS-insoluble cortical tissue samples that were further homogenized in 5 M guanidine HCl were analyzed by ELISA
to determine the guanidine-soluble Aβ40 levels (n = 9–19). E Insoluble Aβ42 levels in the cortex of Cre- and Cre + mice. PBS-insoluble cortex tissue
samples that were further homogenized in 5 M guanidine HCl were analyzed by ELISA to determine the guanidine-soluble Aβ42 levels (n = 9–19).
F Deposition pattern of Aβ plaque and fibrillar amyloid plaque staining in Cre-, Cre+, and APPPS1EKO mice. Representative images are of X-34
(blue) and HJ3.4 (orange) co-stained male brain sections. Scale bars = 50 μm. G Ratio of fibrillar Aβ plaques to total Aβ deposition in Cre-, Cre+, and
APPPS1EKO. The ratio was determined by dividing the area of X-34 staining by the area of HJ3.4 staining. (n = 6–16) (A-F) * p ≤ 0.05, ** p ≤ 0.01, ***
p ≤ 0.001, and **** p ≤ 0.0001; three-way ANOVA and Sidak’s post hoc test in (B) and (C); three-way ANOVA and uncorrected Fisher’s LSD test in (D),
(E), and (G). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
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ChemiDoc™ MP Imaging System (BIO-RAD). Full length
and C-terminal fragments of APP, as well as α-tubulin
bands were captured separately and analyzed by ImageJ
software.
Quantification and statistical analysis

All values were reported as mean ± SEM. All statistical
analyses were conducted in Prism 8 (GraphPad). Twoway or Three-way ANOVA was used for assessing significance between more than two groups. P values less than
0.05 (p < 0.05) were considered significant for all tests.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The significant p values and F values for each experiment can be
found in Supplementary Table 1. The value of n per group
and what n represents in each specific experiment can be
found in the corresponding figure legends and in Supplementary Table 1.

Results
ApoE levels following tamoxifen administration

In order to assess how the loss of astrocytic apoE impacts
Aβ pathology, we used Aldh1l1-Cre/ERT2 BAC transgenic mice to selectively remove APOE from astrocytes
in a tamoxifen dependent manner. APPPS1;FE3Cre + and
APPPS1;FE4Cre + mice (Cre+) were created to assess
Aβ plaque pathology compared to APPPS1;FE3Cre- and
APPPS1;FE4Cre- mice (Cre-). Once-daily intraperitoneal injections of tamoxifen were administered to mice in
each group at 4 weeks of age (2–4 weeks before the initial
formation of Aβ plaques in these mice) for 6 consecutive days (Fig. 1A). All mice received the same series of
tamoxifen injections, including the Cre- mice that served
as the control. A cohort of Cre + and Cre- mice were collected at 6 weeks of age, 1 week after completing tamoxifen administration, and showed no signs of Aβ pathology
(data not shown). To investigate the efficiency of APOE
removal from astrocytes after tamoxifen administration,
we first assessed apoE mRNA and protein levels in the
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brain at 18-weeks of age (Fig. 1A). ApoE mRNA levels
were assessed by qPCR and were significantly reduced
by ~ 70% in the Cre + mice compared to the Cre- mice
(Fig. 1B). To assess apoE protein levels, cortex tissue samples were sequentially extracted in PBS and guanidine
buffers to measure soluble and insoluble apoE, respectively. Soluble apoE levels were also significantly reduced
by ~ 50–70% in all Cre + mice compared to Cre- mice
(Fig. 1C). Insoluble apoE levels, which mostly reflects
apoE co-deposition in Aβ plaques [40, 41], were also significantly reduced in Cre + mice compared to Cre- mice,
with female mice having a ~ 75–85% reduction and male
mice having a ~ 60–65% reduction (Fig. 1D).
Next, we assessed the cell-type-specificity of apoE
expression after tamoxifen administration by performing immunofluorescent staining of apoE (Fig. 1D).
We observed a strong overall reduction in the intensity of apoE staining in the cortex and hippocampus by
~ 60–80% for the Cre + mice compared to the Cre- mice
(Fig. 1E and F). Since apoE is secreted into the extracellular space in lipoprotein particles, the overall intensity
of the apoE immunostaining in both the cortex and hippocampus may be influenced by a combination of both
intracellular and extracellular apoE. Additionally, plaques
are primarily located in the cortex at the ages we studied
and thus the intense foci of apoE staining in the cortex is
likely from apoE associated with amyloid deposits. Qualitative assessment of the staining for apoE also revealed a
strong decrease in the presence of apoE in GFAP+ astrocytes. In the Cre- mice nearly all G
 FAP+ astrocytes were
+
also apoE while the Cre + mice exhibited only rare apoE
staining in GFAP+ astrocytes (Fig. 1G). We also observed
apoE to still be present in Iba1+ microglia, particularly in
the vicinity of Aβ plaques (Fig. 1G). Therefore, the tamoxifen administration was able to effectively reduce the
overall apoE levels and strongly reduce apoE expression
in astrocytes, while appearing to still enable microglial to
express apoE in the Cre + mice. Additionally, while the

(See figure on next page.)
Fig. 4 Microglial activation is reduced in mice with a decrease in astrocytic apoE. A Microglia staining in the cortex and hippocampus of female
Cre- and Cre + mice. Representative images are of female brain sections immunostained using an anti-Iba1 antibody (red). Scale bars = 200 μm. B
Microglial coverage in the cortex of Cre- and Cre + mice. Percent of cortex area covered by microglia was determined by analyzing Iba1 stained
brain sections (n = 10–19). C ApoE+ microglia around fibrillar amyloid plaques in female Cre- and Cre + mice. Representative images are of apoE
immunostaining (green) using an anti-apoE antibody and microglia immunostaining using an anti-Iba1 antibody (magenta) around X-34 stained
(blue) amyloid plaques. ApoE co-localized with Iba1 appears white. Scale bars = 20 μm. D Microglial apoE levels around fibrillar amyloid plaques
in Cre- and Cre + mice. Area of apoE+ microglia per total microglia area was determined by analyzing the level of apoE+ microglia staining to
total microglia staining within 10 μm of X-34 stained plaques (n = 5–12). E Microglia clustering and activated microglia around fibrillar amyloid
plaques in female Cre- and Cre + mice. Representative images are of Clec7a immunostaining (green), using an anti-Clec7a antibody, and microglia
immunostaining using an anti-Iba1 antibody (magenta) around X-34 stained (blue) amyloid plaques. Clec7a co-localized with Iba1 appears white.
Scale bars = 20 μm. F Clustering of microglia around fibrillar amyloid plaques in Cre- or Cre + mice. Area covered by microglia around fibrillar
amyloid plaques was determined by analyzing the level of Iba1 staining within 15 μm of X-34 stained plaques (n = 6–14). G Coverage of activated
microglia around fibrillar amyloid plaques in Cre- or Cre + mice. Area of activated microglia around fibrillar amyloid plaques was determined
by analyzing the level of cleca7a staining within 15 μm of X-34 stained plaques per total area of Iba1 (n = 6–14). A-G * p ≤ 0.05, ** p ≤ 0.01, ***
p ≤ 0.001; three-way ANOVA and uncorrected Fisher’s LSD test in (B), (D), (F), and (G). Data are expressed as mean ± SEM. See Supplementary
Table 1 for detailed statistics
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immunostaining showed that overall apoE levels were
greatly reduced in the Cre + mice, there were still intense
foci of apoE staining co-localized with the X-34+ amyloid
plaques, similar to what was observed in the Cre- mice
(Fig. 1E and G).
Aβ plaque accumulation in mice lacking astrocytic APOE

The deposition of Aβ into fibrillar amyloid plaques is
influenced by the expression level and isoform of apoE.
With the targeted removal of astrocytic APOE resulting in a significant reduction in overall apoE levels, we
investigated what impact this reduction might have
on the deposition of Aβ into 
X34+ fibrillar amyloid
plaques (Fig. 2A, S1). In the cortex and hippocampus,
there was a large and significant decrease in fibrillar plaque load in APPPS1;FE3Cre + females and in
APPPS1;FE4Cre + males and females, while the male
APPPS1;FE3Cre + mice did not show a significant difference (Fig. 2B and C). In the cortex, the female Cre + and
APPPS1;FE4Cre + males had a ~ 60–70% reduction in
amyloid burden and in the hippocampus the reduction
was ~ 75–85%. Overall, the total amyloid burden with
the loss of astrocytic apoE was qualitatively similar to
that observed in APPPS1;EKO mice (Fig. 2B and C). An
analysis of fibrillar plaque intensity revealed Cre + mice
have a significantly reduced overall intensity compared to
the Cre- mice (Fig. 2D and E) and exhibit a smaller, less
dense compact core. The reduction in plaque intensity for
the Cre + mice was ~ 40–55% compared to the intensity
of the Cre- plaques. However, a qualitative assessment
of the APPPS1;EKO mice showed their fibrillar plaques
form with a core that is even less compact and less
intense than the Cre + mice (Fig. 2D and E).
To assess overall Aβ deposition, staining was performed using an anti-Aβ antibody (Fig. 3A, S2A). In the
cortex, male APPPS1;FE3Cre + mice showed no difference in Aβ levels, while female APPPS1;FE3Cre + mice
showed a trend towards lower Aβ plaque load compared to female APPPS1;FE3Cre- mice (Fig. 3B). For the
APPPS1;FE4Cre + mice, both male and female mice had
a significant decrease in cortical plaque coverage of ~ 60%
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compared to APPPS1;FE4Cre- mice (Fig. 3B). In the hippocampus, the Cre + females had significantly lower Aβ
plaque coverage with a ~ 90% reduction (Fig. 3C). Interestingly, a qualitative analysis of the APPPS1;EKO mice
revealed a higher Aβ plaque load than the Cre + mice
(Fig. 3B and C).
To further analyze the accumulation of Aβ in the brain,
the level of insoluble Aβ was assessed in the guanidine
soluble (PBS-insoluble) fractions from homogenized
cortical tissue samples. Both Aβ40 and Aβ42 levels from
the guanidine fraction were assessed by ELISA. Aβ that
is insoluble in PBS and detected in the guanidine fraction serves as a measure of how much Aβ has accumulated in deposits in the brain and constitutes the
majority of the Aβ pool once Aβ aggregates. The Aβ40
and Aβ42 in the PBS soluble fraction showed no difference between each of the groups (data not shown). The
APPPS1;FE3Cre + males showed no difference in Aβ40
and Aβ42 levels in the guanidine fraction compared to the
APPPS1;FE3Cre- male mice while Aβ40 was significantly
decreased in the APPPS1;FE4Cre + males by 65%. Both
the Aβ40 and Aβ42 levels were significantly decreased by
in the Cre + females compared to the Cre- females, with
a ~ 70–80% decrease for Aβ40 and a ~ 50–60% decrease
for Aβ42 (Fig. 3D and E).
An assessment of the Aβ immunostaining in relation
to the formation of fibrillar Aβ plaques also revealed
unique patterns of Aβ deposition in the Cre + mice compared to the Cre- mice (Fig. 3F, S2B). In the Cre + mice,
the fibrillar Aβ core was smaller with a greater percent
of each plaque consisting of non-fibrillar Aβ (Fig. 3F).
However, the APPPS1;EKO mice had an even greater and
more dispersed accumulation of non-fibrillar Aβ than the
APPPS1;FE3Cre + and APPPS1;FE4Cre + mice (Fig. 3F).
In order to assess how much of the total Aβ that was
accumulating was forming fibrillar amyloid structures,
the amount of fibrillar Aβ detected by X-34 staining was
compared to the total Aβ stained by HJ3.4. Immunostaining with HJ3.4 detects all forms of Aβ, so all X-34 positive Aβ plaques will also be detected by HJ3.4 staining,
but not all Aβ detected with HJ3.4 will be positive for

(See figure on next page.)
Fig. 5 Astrocyte activation is reduced in APPPS1;FE4Cre + mice. A Gene expression analysis of S100β in Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-,
and FE4Cre + mice. Graph is of S100β gene levels assessed by qPCR from cortical tissue samples (n = 3–9). B Gene expression analysis of GFAP in
Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graph is of GFAP gene levels assessed by qPCR from cortical tissue samples (n = 3–9).
C Activated astrocyte staining in female Cre- and Cre + mice. Representative images in the top panel are of the cortex and hippocampus from
brain sections immunostained using an anti-GFAP antibody (green). Images in the bottom panels are of GFAP immunostaining (green), using an
anti-GFAP antibody, around X-34 stained amyloid plaques (blue). Scale bars = 200 μm (top panels), 20um (bottom panels). D Astrocyte activation in
the cortex of Cre- or Cre + mice. Percent of cortical area covered by activated astrocytes was determined by analyzing GFAP stained brain sections
(n = 10–14). E Astrocyte activation around fibrillar amyloid plaques in Cre- and Cre + mice. The volume of activated astrocyte processes around
fibrillar amyloid plaques was determined by analyzing the amount of GFAP staining within 15 μm of X-34 stained plaques. GFAP volume was divided
by the X-34 volume to normalize to the amount of plaque and account for differences in plaque size (n = 8–19). A-D * p ≤ 0.05, ** p ≤ 0.01; three
way ANOVA and uncorrected Fisher’s LSD test in (A), (B), (D), and (E). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed
statistics
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X-34. Therefore, comparing the amount of X-34 staining to the total amount of HJ3.4 staining provides insight
into differences in the structural formation of plaques.

The ratio of the X-34 area to HJ3.4 area revealed that
the male Cre + mice had an approximate 65% reduction
in the X-34 to HJ3.4 ratio, while for the females only the
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APPPS1;FE4Cre + mice had a significant reduction in the
ratio of about 50% (Fig. 3G).
Overall, the biochemical results, combined with the Aβ
staining results, show that the loss of astrocytic human
apoE leads to a decrease in overall Aβ pathology compared to mice with no loss of apoE. Additionally, the
loss of astrocytic apoE leads to more diffuse, less fibrillar plaques, though not as diffuse as is seen with a complete knockout of apoE. The loss of astrocytic apoE also
reduces the total amount of fibrillar amyloid plaques that
form in relation to the total amount of Aβ that deposits
in the parenchyma. However, the changes observed in
the overall Aβ plaque load, and in the types of Aβ plaques
that form, could result from changes in the overall APP
levels and/or in the processing of APP that occur with
the loss of astrocytic apoE. To address this concern,
we performed Western blotting of tissue samples for
full-length APP and APP-CTFs and saw no differences
between groups (Fig. S2C, S2D), indicating there were no
differences in APP levels or in the processing APP after
removal of astrocytic apoE.
Microglial activation after the loss of astrocytic apoE

The activation state of microglia has been shown to
be influenced by apoE isoform and the presence of
Aβ plaque pathology in the brain. To better understand how the loss of astrocytic apoE was influencing
microglial gene expression, we performed RT-qPCR
on cortical tissue samples. The APPPS1;FE3Cre- and
APPPS1;FE4Cre- mice exhibited an upregulation of
DAM-associated transcripts compared to FE3 or FE4
mice, respectively, indicative of a microglial response to
amyloid plaques (Fig. S3D-J). The APPPS1;FE3Cre + and
APPPS1;FE4Cre + mice also showed some upregulation
of DAM associated genes, however the increase in these
Cre + mice was reduced in comparison to the Cre- mice
for several of the DAM genes (Fig. S3D-I), including
Clec7a (Fig. S3F).
To assess if the overall levels of microglia were changed
in the Cre + mice, potentially accounting for differences
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in overall DAM gene expression, brain sections were
stained for Iba1 (Fig. 4A). Overall, the % area of the cortex
covered by Iba1 staining remained unchanged between
the APPPS1;FE3Cre + and APPPS1;FE3Cre- mice and
between the APPPS1;FE4Cre + and APPPS1;FE4Cremice (Fig. 4B). However, the apoE3 female mice did show
lower overall Iba1 staining levels than the other groups.
To investigate the state of microglia surrounding Aβ
plaques, an analysis of the amount of Clec7a, a marker
of DAM microglia, was assessed based upon the total
amount of Iba1+ microglia present (Fig. 4E). The amount
of Iba1+ microglia clustering around X-34 plaques was
unchanged between the Cre- and Cre + groups, indicating the loss of astrocytic apoE did not alter the ability of
microglia to migrate to the plaques (Fig. 4F). However the
level of Clec7a was shown to be decreased by ~ 50–70%
around fibrillar plaques in the Cre + mice compared to
the Cre- mice, (Fig. 4G). Furthermore, an assessment of
the presence of apoE (which is also a marker of DAM
microglia) in plaque associated microglia also showed
a significant reduction of ~ 60–70% in Cre + mice compared to Cre- mice (Fig. 4C, D) The reduction of both
microglial apoE and Clec7a levels in Cre + mice suggests
an impaired microglial response to amyloid pathology in
the absence of astrocytic apoE.
Astrocyte activation after the loss of astrocytic apoE

ApoE has been shown to influence certain functions of
astrocytes, including responses to pathogenic stimuli [42,
43], however it is not fully known if the cell-specific loss of
astrocytic apoE alters astrocyte reactivity to Aβ plaques.
Therefore, we assessed the expression profile of genes
involved with astrocyte reactivity by RT-qPCR. Overall
expression of reactive astrocytic genes showed few differences between the Cre- and Cre + mice, including S100β
(Fig. 5A). However, slight decreases of ~ 40–50% in GFAP
expression were seen in the APPPS1;FE4Cre + mice, but
not in the APPPS1;FE3Cre + mice (Fig. 5B). To visualize and further assess astrocyte reactivity, we assessed
GFAP levels by immunostaining (Fig. 5C). Overall GFAP

(See figure on next page.)
Fig. 6 Neuritic dystrophy is increased around plaques, but decreased overall, with a reduction in astrocytic apoE. A Dystrophic neurite staining in
the cortex and hippocampus of Cre- and Cre + mice. Representative images are of brain sections immunostained using an anti-BACE1 antibody
(red). Scale bars = 1000 μm. B Level of neuritic dystrophy in the cortex of Cre- and Cre + mice. Percent of cortical area covered by dystrophic
neurites was determined by analyzing BACE1 stained brain sections (n = 10–19). C Dystrophic neurites around fibrillar amyloid plaques in Cre- and
Cre + mice (BACE1). Representative images are of BACE1 immunostaining (red), using an anti-BACE1 antibody, around X-34 stained (blue) amyloid
plaques. Scale bars = 20 μm. D Level of neuritic dystrophy around fibrillar amyloid plaques in Cre- and Cre + mice (BACE1). Percent of area covered
by dystrophic neurites around fibrillar amyloid plaques was determined by analyzing the level of BACE1 staining within 15 μm of X-34 stained
plaques (n = 6–18). E Dystrophic neurites around fibrillar amyloid plaques in Cre- and Cre + mice (RTN-3). Representative images are of female
RTN-3 immunostaining (red), using an anti-RTN-3 antibody, around X-34 stained (blue) amyloid plaques. Scale bars = 20 μm. F Level of neuritic
dystrophy around fibrillar amyloid plaques in Cre- and Cre + mice (RTN-3). Percent of area covered by dystrophic neurites around fibrillar amyloid
plaques was determined by analyzing the level of RTN-3 staining within 15 μm of X-34 stained plaques (n = 6–14). A-D * p ≤ 0.05, ** p ≤ 0.01, and
**** p ≤ 0.0001; three-way ANOVA and Sidak’s post hoc test in (B); three-way ANOVA and uncorrected Fisher’s LSD test in (D) and (F). Data are
expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
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staining was not altered in APPPS1;FE3Cre + compared to APPPS1;FE3Cre- mice. However, there was
a significant reduction in GFAP staining in the cortex
of female APPPS1;FE4Cre + mice by 36% compared to
APPPS1;FE4Cre- mice (Fig. 5B and C). The reductions
in GFAP gene expression, and in immunostaining, in
APPPS1;FE4Cre + mice could result from altered astrocyte reactivity to amyloid plaques or from overall reductions in amyloid burden. Therefore, to see if astrocyte
reactivity was altered specifically around Aβ plaques,
we assessed GFAP staining within 15 μm of each plaque
(Fig. 5C). No differences were found in the levels of GFAP
staining around plaques between the groups (Fig. 5E).
Since GFAP staining around plaques was unaltered, it
suggests the loss of apoE in astrocytes does not alter the
ability of astrocytes to respond to Aβ plaques, at least
morphologically, but that overall changes to astrocyte
reactivity in the APPPS1;FE4Cre + mice may be driven by
the level of total Aβ plaque pathology.
Neuritic dystrophy after the loss of astrocytic apoE

The deposition of Aβ into fibrillar amyloid plaques results
in damage to surrounding neuronal processes and leads
to the formation of large swollen axons and dendrites
around plaques (neuritic dystrophy). These damaged and
swollen neurites contain accumulations of various proteins that can act as markers for the dystrophy, including
BACE1 [44, 45] and RTN-3 [46, 47]. We used an antiBACE1 antibody to stain and assess the total amount
of dystrophic neurites present in the cortex of mice
(Fig. 6A). The BACE1 levels for the female Cre + mice
were significantly decreased by ~ 50–70% compared to
the female Cre- mice (Fig. 6B). As the BACE-1 positive
dystrophic neurites are only present around amyloid
plaques, this is consistent with overall reductions in amyloid plaque following removal of astrocyte apoE. When
we assessed the area of BACE1 within 15 μm of each
plaque, we found a significant increase in neuritic dystrophy in the male Cre + mice of ~ 30% and an increase
of 50% in female APPPS1;FE4Cre + mice (Fig. 6C and
D). To further assess neuritic dystrophy around plaques,
staining for RTN-3 was also performed (Fig. 6E, S5).
The RTN-3 levels in female Cre + mice were found to be
~ 90–115% higher around plaques than in Cre- females
(Fig. 6F).

Discussion
The influence of APOE genotype on the development of
various neurodegenerative pathologies has been an area
of interest for decades. In particular, the strong effect that
APOE4 has on an individual’s risk for developing Alzheimer disease has been the focus of a tremendous amount
of research. Clinical studies have shown that APOE4
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carriers develop an earlier onset and faster rate of development of Aβ pathology [17, 48]. Previous research has
revealed several ways apoE may influence the buildup of
Aβ and the formation of amyloid plaques [49, 50]. One
way apoE can influence monomeric Aβ levels and its
ultimate aggregation is by competing for clearance via
apoE receptors, like the low-density lipoprotein receptor
(LDLR) or LDL receptor-related protein 1 (LRP1) [12, 37,
51]. The ability of apoE to inhibit Aβ binding and clearance via LDLR and LRP1 is likely an important factor regulating the levels of Aβ in the brain. In addition, apoE can
directly influence Aβ seeding and fibrillogenesis (i.e. the
conversion of monomeric Aβ into oligomeric and fibrillar
structures) [52–57]. However, it is not known if astrocytic
apoE or microglial apoE may be having different effects
on monomeric Aβ clearance and Aβ seeding/fibrillogenesis. While astrocytes are the primary producer of apoE
in the CNS, microglia increase their production of apoE
during the development of neurodegenerative pathology
[28, 29]. Microglia produce and secrete species of human
apoE that have altered glycosylation compared to astrocytes [58]. Additionally, the recent finding by our lab that
microglia secrete human apoE-containing lipoprotein
particles that are smaller and less lipidated than particles
produced by astrocytes [33] points to the potential of
apoE produced by each cell type having unique effects on
the development of Aβ pathology.
For this study, we aimed to answer the question of how
apoE3 and apoE4 specifically produced by astrocytes
influence the formation of Aβ plaques and the subsequent response of cells to the amyloid pathology. In order
to see how astrocytic apoE influences the initial stages of
Aβ plaque development, we aimed to remove APOE prior
to plaque onset. To ensure tamoxifen administration was
occurring prior to the formation of Aβ plaque deposition, a cohort of tamoxifen injected mice was collected at
6 weeks of age, and Aβ immunostaining and X-34 staining showed no signs of any Aβ pathology. The 100 mg/kg
dose of tamoxifen proved to be well tolerated and to efficiently lower APOE mRNA transcripts and to specifically
lower most detectable protein levels of apoE from astrocytes in the Cre + mice. However, because insoluble apoE
in the guanidine fraction is likely apoE bound to amyloid
plaques [40, 41], the decrease in insoluble apoE in the
guanidine fraction of the Cre + mice is likely due to overall Aβ plaque levels being decreased. While the tamoxifen administration did lower apoE levels overall, there
was some variability seen in the efficiency of the injections. Immunostaining for apoE showed very efficient
lowering of apoE and an absence of apoE in the majority of GFAP+ astrocytes; however, some mice had higher
levels of apoE still present and some GFAP+ astrocytes
also still stained positively for apoE. ApoE staining in
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the Cre- mice also appeared to show hippocampal levels
of apoE to be close to cortical levels. While the pattern
we observed of cortical plaque development at 6 weeks
of age and hippocampal development at 3–4 months of
age has been previously described [36], the large differences observed in plaque development despite the level
of apoE appearing to be similar in both regions suggests
other factors besides apoE may be important for regulating plaque deposition in the hippocampus. Nevertheless,
the tamoxifen injections did prove effective in removing
most astrocytic APOE, significantly lowering apoE levels,
with a resultant strong decrease in Aβ pathology.
The reduction in Aβ plaque load observed by selectively decreasing astrocyte apoE3 and apoE4 levels is
similar to the results seen in previous studies that had
reduced apoE in a non-cell specific manner prior to
plaque onset [15, 26]. However, it is worth noting that
sex and apoE isoform-dependent differences were also
observed. In particular, the apoE3 males had far lower
insoluble Aβ levels and Aβ plaque load than the female
and apoE4-expressing mice, which has been previously
observed in both mice and humans [12, 59–62]. Interesting sex differences were also observed with the Crefemale mice having a greater amount of both apoE and
Aβ42 in the guanidine fraction than the Cre- male mice,
suggesting female mice may be more prone to producing apoE that accumulates with insoluble Aβ42. Further
investigations into how sex might influence the role of
astrocytic apoE plays in the development of Aβ pathology
are certainly warranted. Additionally, we observed that
the complete loss of apoE in APPPS1;EKO mice results in
large deposits of diffuse non-fibrillar Aβ, similar to what
we found previously [24], and that the level of diffuse Aβ
deposition in the APPPS1;EKO compared to the selective
removal of astrocyte apoE3 or apoE4 is considerably elevated. However, the very low X-34 to HJ3.4 ratio reveals
that only a small fraction of the Aβ in APPPS1;EKO mice
forms fibrillar plaques. The increased levels of non-fibrillar Aβ deposition in the APPPS1;EKO mice compared to
APPPS1;FE3Cre + and APPPS1;FE4Cre + mice suggests
that the presence of APOE in cells other than astrocytes
may also be influencing overall Aβ deposition to some
extent, though the strong decrease in overall Aβ accumulation resulting from the removal of astrocyte apoE3
and apoE4 suggests astrocytic apoE is a major driver of
Aβ accumulation. While some data suggests that apoE
can affect APP transcription and the production of Aβ
[63], there was no change in the level of overall APP and
APP CTF’s between any of the groups, indicating that
the changes in Aβ plaque load with the loss of astrocytic
apoE are likely not the result of changes in APP levels or
in the production of Aβ. Furthermore, the decrease in the
ratio of X-34 to HJ3.4 staining and the shift in fibrillar
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plaque formation towards less intense and less compact
plaques with the loss of astrocytic APOE indicates astrocytic apoE is influencing the physical structure of the Aβ
plaques that form. Since the structure of Aβ aggregates is
likely driven by direct interactions of apoE and Aβ [52–
55, 57], this suggests that a direct interaction between
astrocyte apoE and some form of Aβ during the process
of seeding or fibrillogenesis is involved in this Aβ structural change. While a complete loss of APOE has shown
similar effects on fibrillar plaque levels and structure
[14, 19, 24, 25], removing only astrocytic APOE in the
APPPS1;FE3Cre + and APPPS1;FE4Cre + mice produced
patterns of Aβ deposition distinct from the APPPS1;EKO.
While very few β-sheet structured fibrils, as detected
by X-34 [64], form in the APPPS1;EKO mice, those that
do form, have a much more dispersed and mesh-like
appearance than the fibrils that form in the Cre + mice.
This suggests the presence or production of APOE in
other cell types, such as microglia, may also be influencing the structure of Aβ plaque formation to some extent
in Cre + mice. For example, fibrillar amyloid plaques
formed in Cre + mice with strongly reduced astrocytic
apoE still contain apoE, which indicates the apoE present
in plaques is likely coming from other cellular sources
such as microglia. In fact, a recent study showed that
the removal of endogenous murine apoE from microglia
results in the formation of dense-core plaques that are
larger in size; however, there was no change in the overall
levels of Aβ plaque load [65].
Another factor that could be impacting the fibrillar
plaque structure is the ability of microglia to interact
with the plaque surface. Previous studies have shown
activated microglia are capable of ‘capping’ the edge of
Aβ plaques to limit the diffusion of Aβ fibrils and aid in
the formation of compact plaques [66, 67]. However, the
low levels of microglial Clec7a and apoE around plaques
in the Cre + mice suggests microglia are not activated to
the same extent as in the Cre- mice. The shift in microglia
activation to a reactive or DAM/MGnD state has been
shown to be apoE dependent [28, 29, 68–70]. Furthermore, astrocytic apoE lipoprotein particles can influence
microglial activation [71, 72], and our results support
the hypothesis that astrocytic apoE may be involved in
signaling pathways between astrocytes and microglia
that regulate the apoE-dependent DAM activation state
of microglia. The transition to the DAM activation state
has been shown to be TREM2-APOE dependent [28] and
apoE is a ligand for TREM2 [73–75]. Decreasing astrocytic apoE may subsequently lower overall TREM2 activation via decreased apoE binding. However, we did not
observe a significant difference in the overall TREM2
transcript levels between the Cre- and Cre + groups and
it is possible astrocyte-derived apoE may be involved in
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microglial activation via another yet to be determined
mechanism. Additionally, since activated microglia are a
source of plaque-associated apoE [34], decreased microglial activation may result in decreased microglial apoE
production, as suggested by our results, and thus a reduction in the amount of microglial apoE binding to Aβ to
aid in fibrillar plaque formation and plaque compaction.
The reduction in either astrocytic apoE3 or apoE4 had
similar impacts on lowering Aβ plaque levels, as well as
on reducing the activation of microglia surrounding Aβ
plaques. This suggests that the influence of apoE isoforms
on Aβ that have been previously observed in mouse
models may not solely be driven by the expression of
ApoE3 or ApoE4 by astrocytes, but rather by expression
of apoE from other cell types, such as microglia. While
the decrease in overall DAM gene expression in the
Cre + mice may be driven by the overall Aβ plaque load
being lower than the Cre- mice, the reduction in microglial activation around plaques, as marked by decreased
Clec7a and apoE staining around plaques, indicates the
loss of astrocytic apoE is having a local effect on the state
of microglia as well. We also observed isoform- and sexdependent differences in total astrocyte activation as
measured by GFAP staining. Again, while the decrease in
overall GFAP levels in the APPPS1;FE4Cre + mice may be
explained by decreased Aβ plaque load, the lack of a difference in overall GFAP levels in APPPS1;FE3Cre + mice
suggests that astrocytic apoE3 may be having a differential effect on reactive astrogliosis compared to astrocytic
apoE4. Indeed, induced expression of apoE3 by astrocytes
has been shown to lower overall GFAP levels [27]. It will
be important in future studies to utilize methods such as
single cell RNA sequencing of astrocytes, to more fully
explore the apoE isoform and sex-dependent changes in
reactive astrogliosis that are present in different disease
conditions, including in the presence of amyloid [76].
The impact of apoE on microgliosis at sites of Aβ
plaque deposition can lead to changes in damage to surrounding cells, including the formation of dystrophic
neurites (neuritic dystrophy) [72]. Neuritic dystrophy has
been shown to be increased around fibrillar plaques with
a more dispersed morphology than around dense core
plaques with a compact morphology [24, 66, 77–79]. The
removal of astrocyte apoE strongly reduced the amount
of fibrillar plaques and plaque-associated neuritic dystrophy, as indicated by reduced BACE1 and RTN-3 accumulation. However, the change in fibrillar plaque formation
to a more dispersed and less compact structure observed
in the APPPS1;FE3Cre + and APPPS1;FE4Cre + mice
may be driving the increased neuritic dystrophy around
the remaining fibrillar plaques present in these mice
as is seen in the absence of apoE and TREM2 [24, 66].
Additionally, apoE lipoprotein particles produced by

Page 17 of 20

astrocytes have been shown to support neuronal function and recovery following neuronal damage [80–84].
The loss of astrocytic apoE could reduce astrocytic support to damaged neuritic processes that develop at sites
of Aβ plaques and contribute to the increase in neuritic
dystrophy. Finally, while Aβ plaques were detected in
the hippocampus, and intense BACE1 staining of the
mossy fibers of the hippocampus was observed, analysis of BACE1 in the hippocampus was not performed
because of the small number of plaques present. The
intense BACE1 mossy fiber staining has been previously
reported and plays a role in normal physiological function and is not indicative of any neuronal damage akin to
neuritic dystrophy [85–87]. However, given the decrease
in overall neuritic dystrophy while dystrophy around
plaques is increased, further studies are needed to better
understand how the loss of astrocytic apoE is impacting
overall neuronal function.

Conclusion
We demonstrate that reducing astrocytic apoE3 and
apoE4 results in a strong decrease in both fibrillar
amyloid plaques and overall Aβ plaque deposition in
APPPS1;FE3Cre + and
APPPS1;FE4Cre + mice.
We
also found that the loss of astrocytic apoE results in the
structure and pattern of Aβ deposition being altered in a
unique manner compared to the complete loss of apoE in
APPPS1;EKO mice. Furthermore, the decrease in microglial activation surrounding fibrillar plaques following
removal of astrocyte apoE demonstrates astrocytic apoE
may be playing a critical role in regulating microglial
responses to Aβ pathology. Isoform-dependent effects
on astrocyte activation were also seen and suggest astrocytic apoE3 may act to reduce overall astrocyte activation. Finally, while the more dispersed fibrillar plaque
structures seen in the Cre + mice were shown to induce
an increase in neuritic dystrophy at the site of Aβ plaque
deposition, the ability of reducing astrocytic apoE to
lower Aβ plaque levels led to an overall decrease in levels
of neuritic dystrophy. These results demonstrate the therapeutic potential of using targeted cell-specific reduction of astrocytic apoE to ameliorate Aβ pathology that is
found in Alzheimer disease.
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Additional file 1 : Figure S1. Fibrillar amyloid plaque staining in the cortex and hippocampus of male Cre- and Cre + mice. Representative images
are of X-34 (blue) stained male brain sections. Scale bars = 1000 μm.
Additional file 2 : Figure S2. (A) Aβ plaque staining in the cortex and
hippocampus of male Cre- and Cre + mice. Representative images are of
Aβ immunostained male brain sections using the HJ3.4 anti-Aβ antibody
(orange). Scale bars = 1000 μm. (B) Deposition pattern of Aβ plaque and
fibrillar amyloid plaque staining in female Cre- and Cre + mice. Representative images are of X-34 (blue) and HJ3.4 (orange) co-stained brain
sections. Scale bars = 50 μm. (C) Western blots of full-length APP and APPCTFs for Cre- and Cre + mice. Images are of blots that used an anti-APP
C-terminal antibody and an anti-α-tubulin antibody. For each group, n = 3
males and n = 3 females were used. (D) Level of APP and APP-CTFs in Creand Cre + mice. The density of each band was determined using ImageJ
software. APP and APP-CTF values were normalized to α-tubulin (n = 6).

Additional file 3 : Figure S3. (A-J) Microglial gene expression analysis
in Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graphs
are of genes assessed by qPCR from cortical tissue samples (n = 3–9). *
p ≤ 0.05, ** p ≤ 0.01; three way ANOVA and uncorrected Fisher’s LSD test
in (A-J). Data are expressed as mean ± SEM. See Supplementary Table 1 for
detailed statistics.
Additional file 4 : Figure S4. Gene expression analysis of Serpina3n in
Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graph is of the
Serpina3n gene assessed by qPCR from cortical tissue samples (n = 3–9).
* p ≤ 0.05; three way ANOVA and uncorrected Fisher’s LSD test. Data
are expressed as mean ± SEM. See Supplementary Table 1 for detailed
statistics.
Additional file 5 : Figure S5. Dystrophic neurites around fibrillar amyloid
plaques in Cre- and Cre + mice (RTN-3). Representative images are of male
RTN-3 immunostaining (red), using an anti-RTN-3 antibody, around X-34
stained (blue) amyloid plaques. Scale bars = 20 μm.
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